Shares climbed 4.4% following PROCEPT BioRobotics’ Q1 2026 results, as investors responded positively to accelerated margin recovery, record system pricing, and confirmation of the company’s full-year profitability and growth objectives.

• Q1 2026 revenue reached $83.1 million, up 20% year-over-year, in line with management’s stated expectations despite modest procedural impact from commercial realignment.
• Gross margin improved sharply to 65%, up from 61% in Q4 2025, reaching the company’s full-year guidance three quarters early; management now expects further sequential margin gains throughout 2026.
• U.S. Hydros system average selling price hit an all-time high of ~$485,000 (14% increase vs. Q4 2025), while handpiece ASPs rose 5% quarter-over-quarter and 10% year-over-year.
• Company reiterates full-year system placement plans, with 49 U.S. Hydros systems sold in Q1 (including 2 replacements) and strong initial response to the AQUABEAM replacement program.
• International expansion advanced with 7 Hydros systems sold in the UK and continued pipeline growth; regulatory momentum included a major clinical guideline upgrade in Europe and FDA clearance of second-generation software.